Ranbaxy launches Urology Drug Roliflo* OD

39737 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy launches Urology Drug Roliflo* OD

Ranbaxy launches Urology Drug Roliflo* Od based on Multiparticulate Ndds Technology

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy gets approval for Hydrocodone Bitartrate Buy Ranbaxy Lab; with upside of 28%: Edelweiss Block deal in Ranbaxy Lab, stock gains 3.5% Ranbaxy: In top 5 pharma club by 2012? ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (RLL) today announced the launch of Roliflo* OD (combination of Tamsulosin and Tolterodine) brand in the Indian market for the management of  " bladder outlet obstruction with concomitant overactive bladder", a chronic urological disorder. This is a Novel Drug Delivery System (NDDS) product, which is being introduced for the first time in India.

Roliflo* OD will be sold as  a once-a-day combination of  Tolterodine tartarate extended release 4mg and Tamsulosin hydrochloride extended release 0.4mg dosage capsules.

Commenting on the launch, Mr Sanjeev Dani, Sr. Vice President & Regional Director - Asia & CIS, Ranbaxy, said: "Roliflo* OD will provide the urologists with an improved treatment option for patients suffering from this highly uncomfortable condition.  Ranbaxy is the leader in the Urology segment and the introduction of Roliflo OD based on our proprietary Multiparticulate NDDS technology further reinforces our leadership position indelivering novel therapeutic options, to urologists  in the Indian Market."

Overactive bladder in patients with bladder outlet obstruction largely remains under-treated due to the occurrence of side effects with currently available options in such patients. Roliflo OD has demonstrated clinical tolerability of antimuscarinics during various clinical trials due to the specially designed NDDS profile of  the product. The  extended release of the medicine in the human body is made possible because of the polymer coated beads of Tolterodine tartrate & Tamsulosin Hydrochloride, that are packed   in  a capsule, to enable only once a day administration . This signifcantly enhances patient convenience and improves compliance .

Five out of every ten individuals above 40 years are believed to suffer from benign prostatic hyperplasia (enlarged prostate) with concomitant overactive bladder (OAB). The problem is equally common among men and women in both rural and urban population. 

Sourced From: Ranbaxy Laboratories Ltd